Virtus Investment Advisers, Inc. Halozyme Therapeutics, Inc. Transaction History
Virtus Investment Advisers, Inc.
- $112 Million
- Q2 2024
A detailed history of Virtus Investment Advisers, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 3,927 shares of HALO stock, worth $232,399. This represents 0.18% of its overall portfolio holdings.
Number of Shares
3,927
Previous 3,927
-0.0%
Holding current value
$232,399
Previous $159,000
28.93%
% of portfolio
0.18%
Previous 0.12%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
487Shares Held
123MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$762 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$344 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$239 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$220 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...